The Solitary Bone Metastasis as a First Sign of Papillary Thyroid Cancer

2012 ◽  
Vol 8 (2) ◽  
pp. 289-294 ◽  
Author(s):  
Radenko Stojanic
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastasis ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Solitary Bone Metastasis

scholarly journals MON-530 Local Lymph Node Metastasis Is Less Common in RAS- Mutated Thyroid Cancer Compared to BRAFV600E- Mutated Thyroid Cancer

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Mayumi Endo ◽  
Fadi Nabhan ◽  
Pamela Brock ◽  
Katie Roll ◽  
Jennifer Anne Sipos ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Bone Metastasis ◽  
Lymph Node Metastasis ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Brafv600e Mutation ◽  
Ras Mutation ◽  
Node Metastasis ◽  
Local Lymph Node

Abstract Introduction: Somatic mutations of RAS- and BRAFV600E- are the most common driver mutation in thyroid cancer (TC) and in the majority of cases, these are mutually exclusive1,2. Clinical characteristics of TC with either RAS or BRAFV600E mutation is not systemically studied. Methods: This is a retrospective study at the Ohio State University (OSU) from 1/2000 to 12/2018. Data were extracted from OSU Endocrine Neoplasia Repository (ENR). Medullary thyroid cancer was excluded. The treating physician determined patient management. Statistical analysis was performed with the chi-square test for categorical values and Mann-Whitney U test for continuous unpaired values. Two-sided P values of less than 0.05 were considered statistically significant. Results: Out of 320 patients, 152 patients had a positive mutational profile. Of these, 128 patients had a BRAFV600E mutation and 14 had a RAS mutation. Details of RAS mutation were as follows; NRASQ61K (n=2), NRASQ61R (n=1), HRASQ61R (n=1), HRASQ61K (n=1), NRAS without further details (n=9). Local lymph node metastasis was significantly less in RAS mutated cancer (58% vs 16%, p<0.05). Lymph node metastasis was limited to N1a in all RAS group, whereas 38% of BRAFV600E had N1b status. The number of positive lymph nodes were significantly fewer in the RAS group (mean 0.42 vs. 9.1, p=0.003). None of the patients in RAS group developed subsequent local neck recurrence, whereas 19% of BRAFV600E group developed a recurrence (p=0.05). Bone metastasis was more common in RAS compared to BRAFV600E group (21% vs 6%, p=0.04) but there were no differences in other distant metastases. Presence of extrathyroidal extension was significantly higher in BRAFV600E compared to RAS group (58 % vs 8%; p=0.04). Classic variant papillary thyroid cancer was the most common histologic diagnosis with both mutations, however, follicular-variant papillary thyroid cancer was more common in RAS than BRAFV600E group (29% vs 8%, p=0.04) and follicular thyroid cancer was only seen in the RAS group (25% vs 0%, p<0.05). There was no difference in gender, age at diagnosis, disease status after initial therapy, RAI treatment, RAI dosage, and mortality between the groups. Conclusion: Thyroid cancer associated with a RAS-mutation has less tendency to metastasize locally and has a higher incidence of bone metastasis compared to thyroid cancer with BRAFV600E-mutation. Individualized clinical follow up may be indicated depends on their mutational profile. References: 1. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676-690. 2. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318-2326.

scholarly journals Thyroid papillary carcinoma presenting with femoral neck metastasis: a case report

2016 ◽  
Vol 2 (3) ◽  
pp. 204
Author(s):  
Birol Aktas ◽  
Mehmet Esat Uygur ◽  
Mehmet Salih Soylemez ◽  
Bahattin Kemah ◽  
Bilge Bilgic ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Femoral Neck ◽  
Papillary Thyroid Cancer ◽  
Metastatic Tumor ◽  
Papillary Thyroid ◽  
Hyperintense Lesion ◽  
Laboratory Findings ◽  
Thyroid Papillary ◽  
Solitary Bone Metastasis ◽  
Thyroid Papillary Cancer

<p>Thyroid carcinoma is relatively uncommon, accounting for 2% of all cancers. Although they usually present as a neck lump, occasionally they may be presented with a distant metastasis. In this study, a 65 year-old woman was referred to our clinic with a pain on her left hip at both rest and walking. A lytic area at the inferior femoral neck was found with plain radiography. To clarify the characteristics of the lesion, left hip magnetic resonance imaging (MRI) had been performed displaying 3×5 cm hyperintense lesion extending from medial part of the left femoral neck to the left femoral head. Laboratory findings were normal. An open biopsy had then been performed from the left femoral neck with a suspicion of a metastatic tumor. After Immunohistochemical assesment diagnosis was consistent with metastatic thyroid papillary cancer. Proximal femoral resection with clear margins were achieved by proximal femur tumor endoprosthesis.  In conclusion, papillary thyroid cancer have an excellent prognosis and doesn’t tend to metastese. But rarely, as seen in our case it can even present with syptoms of metastasic disease. Management strategy is the same as other solitary bone metastasis. Papillary thyroid cancer must be kept in mind as a differential diagnosis in solitary bone metatasis.</p>

Abstract #1086: Patient Experience with Severe Low Energy Following Total Thyroidectomy for Papillary Thyroid Cancer

2017 ◽  
Vol 23 ◽  
pp. 258
Author(s):  
Elizabeth Wendt ◽  
Maria Bates ◽  
Reese Randle ◽  
Jason Orne ◽  
Cameron Macdonald ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Papillary Thyroid Cancer ◽  
Patient Experience ◽  
Low Energy ◽  
Papillary Thyroid
Sign in / Sign up

Export Citation Format

Share Document